



**Final Appraisal Recommendation**

Advice No: 1119 – September 2019

**Buprenorphine (Buvidal®) 8 mg, 16 mg, 24 mg, 32 mg, 64 mg, 96 mg and 128 mg prolonged-release solution for subcutaneous injection**

**Submission by Camurus AB**

**Recommendation of the All Wales Medicines Strategy Group**

**Buprenorphine (Buvidal®) is recommended as an option for use within NHS Wales for the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3977), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1119: Buprenorphine (Buvidal®) 8 mg, 16 mg, 24 mg, 32 mg, 64 mg, 96 mg and 128 mg prolonged-release solution for subcutaneous injection.  
September 2019